Skip to main content

2022 News



Tuesday, August 09, 2022

New Study Confirms Typhoid Vaccine Safety, Immune Response in Children

A new study, published in The Lancet Global Health, finds typhoid conjugate vaccine, Typbar TCV®, provides immunity for up to 3 years in children as young as 9 months old in Malawi. The research – conducted by the Blantyre Malaria Project, Malawi-Liverpool-Wellcome Trust, and researchers at the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM) – found that the TCV vaccine is safe and well tolerated. Importantly, the vaccine can be given to 9-month-old infants at the same time as routine measles-rubella vaccinations without reducing the immune response to either vaccine.


Monday, August 08, 2022

New Study Finds Rapid Decline in Vaccine-Boosted Neutralizing Antibodies Against Omicron Subvariant BA.5

A study led in part by investigators at the University of Maryland School of Medicine’s (UMSOM) Center for Vaccine Development and Global Health found that although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, those antibody levels decrease substantially within three months. Kirsten E. Lyke, MD, Professor of Medicine at UMSOM and scientist at CVD, is Co-Chair and site Principal Investigator for the study, and Meagan Deming, MD, PhD, Assistant Professor of Medicine at the UMSOM, also a scientist at CVD, is Vice-Chair of the study, which is a collaboration between investigators at the UMSOM’s CVD and the Institute of Human Virology (IHV).


Monday, July 25, 2022

University of Maryland School of Medicine Expert Co-led Novavax Trial that Led to FDA Emergency Use Authorization and CDC Recommendation

The Centers for Disease Control and Prevention (CDC) this week recommended a new COVID-19 protein-based vaccine as an option for primary vaccination of adults 18 years of age and older. The University of Maryland School of Medicine’s (UMSOM) Karen Kotloff, MD, Professor of Pediatrics, Medicine, Epidemiology, and Public Health, co-led the multi-center PREVENT-19 clinical trial, which studied safety and efficacy of the Novavax vaccine in about 30,000 adult study participants.


Monday, July 18, 2022

New Genomic Research Shows Why Testing Malaria Vaccines in the Clinic is as Rigorous as Natural Exposure in the Field

Malaria is the deadliest mosquito-borne parasitic infection of humans. In 2021, after a century of research, the World Health Organization (WHO) approved the world’s first malaria vaccine. That vaccine reduces the incidence of malaria infections in young children aged 5-17 months by only 30 percent, meaning that it remains critical to continue developing and testing more effective vaccines.


Wednesday, May 25, 2022

NIH Awards Grant to Train Global Health Scientists in Low-and-Middle-Income Countries

Researchers at the University of Maryland School of Medicine (UMSOM) received a $5.5 million award from the National Institute of Health’s Fogarty International Center to help foster the next generation of global health scientists. The award entitled, “Integrated Network of Scholars in Global Health Research Training (INSIGHT)” will expand global health research across sub-Saharan Africa, South Asia, Latin America, and the Caribbean by providing one-year mentored research training to U.S. and lower-middle income country scholars.


Thursday, March 24, 2022

UM School of Medicine Leads Research to Assess Meningococcal Vaccine for Infants and Young Children in Africa

Researchers at the University of Maryland School of Medicine (UMSOM)’s Center for Vaccine Development & Global Health (CVD) are leading a study to evaluate the use of a pentavalent – or five in one – meningococcal conjugate vaccine (NmCV-5) among infants and young children in the meningitis belt of sub-Saharan Africa. This is the final and pivotal study for World Health Organization (WHO) prequalification of this vaccine, which is the last stage to make the vaccine available for low- and middle-income countries.


Wednesday, March 16, 2022

Two University of Maryland School of Medicine Women Faculty Leaders Featured in New Book

Dr. Kathleen Neuzil and Dr. Donna L. Parker are Two of 33 Women Included in Case Studies Featured in Lessons Learned: Stories from Women Physician Leaders


Wednesday, January 26, 2022

Trial Co-led by University of Maryland School of Medicine Scientist Confirms Safety of “Mix-and-Match” COVID-19 Vaccine Booster Dosing

A University of Maryland School of Medicine (UMSOM), Center for Vaccine Development and Global Health (CVD), expert is co-leading an ongoing study that was pivotal in recommending adults and teens receive booster COVID-19 shots of their choosing starting in fall 2021. The preliminary clinical trial results, reported today in The New England Journal of Medicine, found that is safe and effective to receive boosters that are the same or a different one from the person’s primary vaccine(s).